2025 Hyper Recent •CC0 1.0 Universal

This work is dedicated to the public domain. No rights reserved.

Access Preprint From Server
January 22nd, 2025
Version: 6
Sichuan University
cancer biology
biorxiv

PA28γ promotes the malignant progression of tumor by elevating mitochondrial function via C1QBP

Wang, J.Open in Google Scholar•Shi, Y.Open in Google Scholar•Wang, Y.Open in Google Scholar•Shen, Y.Open in Google Scholar•Liu, H.Open in Google Scholar•Sun, S.Open in Google Scholar•Wang, Y.Open in Google Scholar•Zhou, X.Open in Google Scholar•Zhou, Y.Open in Google Scholar•Zeng, X.Open in Google Scholaret al.

Proteasome activator 28{gamma} (PA28{gamma}) plays a critical role in malignant progression of various tumors, however, its role and regulation are not well understood. Here, using oral squamous cell carcinoma (OSCC) as main research model, we discovered that PA28{gamma} interacted with complement 1q binding protein (C1QBP), which is dependent on the N-terminus of C1QBP rather than the known functional domain (amino acids 168-213). Notably, we found that PA28{gamma} enhances C1QBP protein stability in OSCC. Functionally, PA28{gamma} contributes to the malignant progression of OSCC by affecting mitochondrial morphology and oxidative phosphorylation (OXPHOS) through C1QBP in vitro and vivo. Mechanically, PA28{gamma} upregulates the expression of optic atrophy 1 (OPA1), mitofusin 1 (MFN1), mitofusin 2 (MFN2), and the mitochondrial respiratory complex via C1QBP. Moreover, in a clinical cohort of OSCC patients, PA28{gamma} was positively correlated with C1QBP expression and negatively correlated with prognosis. Therefore, C1QBP represents a potential therapeutic target for cancer treatment and prognosis.

Similar Papers

biorxiv
Wed Jan 22 2025
PI3K regulates TAZ/YAP and mTORC1 axes that can be synergistically targeted
Purpose: Sarcomas are a heterogeneous group of cancers with few shared therapeutic targets. PI3K signaling is activated in various subsets of sarcomas, representing a shared oncogenic signaling pathway. Oncogenic PI3K signaling has been challenging to target therapeutically. An integrated view of PI3K and Hippo pathway signaling is examined to determine if this could be leveraged therapeutically. ...
Garcia, K. C.
•
Khan, A. A.
•
Ghosh, K.
•
Sinha, S.
...•
Tanas, M. R.
biorxiv
Tue Jan 21 2025
ADAR1 Regulates Lipid Remodeling through MDM2 to Dictate Ferroptosis Sensitivity
Triple-negative breast cancer (TNBC), lacking expression of estrogen, progesterone, and HER2 receptors, is aggressive and lacks targeted treatment options. An RNA editing enzyme, adenosine deaminase acting on RNA 1 (ADAR1), has been shown to play important roles in TNBC tumorigenesis. We posit that ADAR1 functions as a homeostatic factor protecting TNBC from internal and external pressure, includi...
Kung, C.-P.
•
Terzich, N. D.
•
Ilagan, M. X. G.
•
Prinsen, M. J.
...•
Weber, J. D.
biorxiv
Tue Jan 21 2025
Concurrent PIK3CA mutant drives cachexia through inflammatory signaling in EGFR mutant lung cancer
PIK3CA mutation is frequently concurrent with known oncogenic drivers such as EGFR mutation in lung cancer, raising an interesting question about its real function. Cachexia is a systemic disease involving complex interaction between primary tumors and distant organs, significantly contributing to cancer-related mortality. Through integrative study of genetically engineered mouse models (GEMMs) an...
Yue, M.
•
Qin, Z.
•
Tang, S.
•
Cai, X.
...•
Ji, h.
biorxiv
Tue Jan 21 2025
GLUT5 armouring enhances adoptive T cell therapy anti-tumour activity under glucose-limiting conditions
Cancer immunotherapy with engineered T cells has become a standard treatment for certain hematologic cancers. However, clinical trial outcomes for solid tumours are significantly lagging. A primary challenge in solid tumours is the lack of essential metabolites in the tumour microenvironment, such as glucose, due to poor vascularization and competition with tumour cells. To address this, we modifi...
Page, R.
•
Martinez, O.
•
Larcombe-Young, D.
•
Bugallo-Blanco, E.
...•
Perucha, E.
biorxiv
Tue Jan 21 2025
In depth profiling of the cancer proteome from the flowthrough of standard RNA-preparation kits for precision oncology
Cancer is a highly heterogeneous disease, even within the same patient. Biopsies taken from different regions of a tumor may stand in stark molecular contrast to each other. Therefore, the ability to generate meaningful data from multiple platforms using the same biopsy is crucial for translating multi-omics characterizations into the clinic. However, it is generally a cumbersome and lengthy proce...
Mundt Madsen, F.
•
Nielsen, A. B.
•
Wang, J.
•
Duel, J. K.
...•
Mann, M.
biorxiv
Mon Jan 20 2025
TMPRSS2-ERG confers resistance to antiandrogens: mechanism and therapeutic implications
Approximately 50% of prostate cancer (PCa) patients harbor fusions involving the TMPRSS2 and ERG genes. Despite this, tailored therapies targeting the fused gene, tERG, remain undeveloped. Our study analyzed biopsy samples from two clinical trials assessing the efficacies of androgen receptor (AR) signaling inhibitors (ARSIs). The results revealed that tERG promotes resistance to ARSIs and is asso...
Sekar, A.
•
Chatterjee, R.
•
Selvadurai, B. R.
•
Ray, L.
...•
Yarden, Y.
biorxiv
Mon Jan 20 2025
DNA polymerase beta expression in head & neck cancer modulates the poly(ADP-ribose)-mediated replication checkpoint
Head and Neck Squamous Cell Carcinoma (HNSCC) imposes a significant health burden, necessitating innovative therapeutic strategies to enhance treatment efficacy. Current treatments such as surgery, radiation, and chemotherapy have limited effectiveness and yield severe side effects, emphasizing the need for targeted therapies. We have focused on DNA polymerase beta (Pol{beta}) and its roles in rep...
Khan, M. M.
•
Roos, W. P.
•
Angajala, A.
•
Gibbs, D. Y.
...•
Sobol, R. W.
biorxiv
Mon Jan 20 2025
SPARC is a new driver of early breast tumor progression via TGF-β -dependent mechanism.
The transition of ductal carcinoma in situ (DCIS) to an invasive stage is a crucial event that involves the disruption of the basement membrane and the physical connection of the neoplastic cells with the surrounding stroma. A better understanding of the mechanisms and actors involved in progression to invasive disease will improve treatment outcomes. Membrane type 1 (MT1)-matrix metalloproteinase...
Sciacca, M.
•
Carballo, M. d. P.
•
Lacunza, E.
•
Marino, L.
...•
Lodillinsky, C.
biorxiv
Mon Jan 20 2025
Optical imaging of treatment-naive human NSCLC reveals changes associated with metastatic recurrence
Lung cancer remains the leading cause of cancer deaths, comprising nearly 25% of all cancer deaths [1]. NSCLC accounts for approximately 85% of all cases and encompasses major subtypes such as adenocarcinoma and squamous cell carcinoma. Despite advances in surgical and therapeutic options, NSCLC remains associated with poor prognosis due to a high rate of recurrence, even in early stages. Around 3...
Diaz, P. M.
•
Ivers, J. D.
•
Byrum, S. D.
•
Quick, C. M.
...•
Rajaram, N.